Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Sanofi-aventis
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
A double-blind placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40mg for 12 weeks in patients with mild to moderate Alzheimer's Disease
To assess the activity of AVE1625 at the doses of 10 and 40 mg/day in comparison to placebo in patients with mild to moderate Alzheimer Disease: - Safety and tolerability by monitoring of adverse even...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis Research & Development
MAJ Il y a 4 ans
TDU13828: First-in-human Study with Ascending Single Intra-articular Doses of GZ389988A in Patients with Painful Osteoarthritis of the Knee ACT13830: Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intra-articular Dose of GZ38998A versus Placebo in Patients with Painful Osteoarthritis of the Knee
TDU13828: To assess the safety and tolerability of ascending single intra-articular doses of GZ389988A in patients with painful osteoarthritis (OA) of the knee. ACT13830: To assess the efficacy o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
A multicenter clinical trial to evaluate quality of life in patients with Type 2 diabetes before and after changing therapy to a combination of insulin glargine and oral antidiabetic drugs in a real life situation
To assess QoL changes and treatment satisfaction in a real life situation in patients with Type 2 diabetes inadequately controlled on a combination of OAD + NPH insulin treatment that are switched to ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting
To demonstrate non-inferiority of once daily injection of insuline glargine (Lantus®) plus one injection of mealtime insulin glulisine (Apidra®) at the main meal versus twice daily premixed insulin (N...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
Population pharmacokinetics study with Amaryl® (Glimepiride) in pediatric and adult population with type 2 diabetes
To investigate the pharmacokinetics of Amaryl® in pediatric patients (8 to 16 years of age) with type 2 diabetes in comparison with adults patients (17 years or older of age) with type 2 diabetes unde...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis U.S. Inc
MAJ Il y a 4 ans
A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis
To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurren...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSistent Atrial Fibrillation requiring conversion of AF
The primary objective of the study is to evaluate the rate of AF recurrences one month after randomization according to different timings of initiation of dronedarone.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis U.S. Inc
MAJ Il y a 4 ans
A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis
To investigate the tolerability and safety of a 7 mg and a 14 mg dose of teriflunomide administered once daily for 24 weeks, compared with placebo in subjects with multiple sclerosis who are concurren...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
Safety and Efficacy of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Central Nervous System Tumors
Phase 1 Part: To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cabazitaxel as a single agent in pediatric patients with recurrent or refractory solid tumors ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Sanofi-aventis
MAJ Il y a 4 ans
A clinical trial to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain. Klinikai vizsgálat a nem múló daganatos fájdalom kiegészítő kezelésére alkalmazott SSR411298 készítmény klinikai előnyeinek értékelésére
• To evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain, as measured by the change from baseline (baseline = average pain intensity ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
Suivant